HK Stock Market Move | HAIXI PHARMA (02637) rose more than 4% in early trading. HXP056 has completed Phase I clinical recruitment and started Phase II research.

HAIXI PHARMA (02637) rose more than 4% in the morning session, up 3.42% as of press time, at HK $148, with a turnover of HK $19.46 million. On the news front, HAIXI PHARMA announced that HXP056 has started a phase I clinical trial for Chinese wAMD patients in early July 2025. The recruitment of all patients in the single-dose escalation (SAD) and multiple-dose escalation (MAD) stages has been completed, with dose-limiting toxicity (DLT) assessment and pharmacokinetic (PK) data collection to be carried out after four weeks of continuous dosing. Preliminary efficacy assessment is also underway. In the fourth quarter of 2025, the company has initiated a phase II clinical dose expansion study. It is worth noting that HAIXI PHARMA has been officially included in the Hong Kong Stock Connect list since March 9. Mainland investors who meet the criteria for investing in Hong Kong stocks can directly trade the company's H-shares listed on the Hong Kong Stock Exchange through the Stock Connect mechanism under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect.